Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has received regulatory approvals for its Clinical Trial Applications for the next studies of both of its lead candidates.
Source: Street Insider
